

By the Committees on Appropriations; and Health Policy; and
Senator Grimsley

576-04910-13

2013732c2

1 A bill to be entitled

2 An act relating to pharmacy; amending s. 465.019,
3 F.S.; permitting a Class II institutional pharmacy
4 formulary to include biologics, biosimilars, and
5 biosimilar interchangeables; creating s. 465.0252,
6 F.S.; providing definitions; providing requirements
7 for a pharmacist to dispense a substitute biological
8 product that is determined to be biosimilar to and
9 interchangeable for the prescribed biological product;
10 providing notification requirements for a pharmacist
11 in a Class II or Modified Class II institutional
12 pharmacy; requiring the Board of Pharmacy to maintain
13 a current list of interchangeable biosimilar products;
14 providing an effective date.

15
16 Be It Enacted by the Legislature of the State of Florida:

17
18 Section 1. Subsection (6) of section 465.019, Florida
19 Statutes, is amended to read:

20 465.019 Institutional pharmacies; permits.-

21 (6) In a Class II institutional pharmacy, an institutional
22 formulary system may be adopted with approval of the medical
23 staff for the purpose of identifying those medicinal drugs, and
24 proprietary preparations, biologics, biosimilars, and biosimilar
25 interchangeables that may be dispensed by the pharmacists
26 employed in such institution. A facility with a Class II
27 institutional permit which is operating under the formulary
28 system shall establish policies and procedures for the
29 development of the system in accordance with the joint standards

576-04910-13

2013732c2

30 of the American Hospital Association and American Society of
31 Hospital Pharmacists for the utilization of a hospital formulary
32 system, which formulary shall be approved by the medical staff.

33 Section 2. Section 465.0252, Florida Statutes, is created
34 to read:

35 465.0252 Substitution of interchangeable biosimilar
36 products.—

37 (1) As used in this section, the terms "biological
38 product," "biosimilar," and "interchangeable" have the same
39 meanings as defined in s. 351 of the federal Public Health
40 Service Act, 42 U.S.C. s. 262.

41 (2) A pharmacist may only dispense a substitute biological
42 product for the prescribed biological product if:

43 (a) The United States Food and Drug Administration has
44 determined that the substitute biological product is biosimilar
45 to and interchangeable for the prescribed biological product.

46 (b) The prescribing health care provider does not express a
47 preference against substitution in writing, verbally, or
48 electronically.

49 (c) The pharmacist notifies the person presenting the
50 prescription of the substitution in the same manner as provided
51 in s. 465.025(3) (a).

52 (d) The pharmacist retains a written or electronic record
53 of the substitution for at least 2 years.

54 (3) A pharmacist who practices in a Class II or Modified
55 Class II institutional pharmacy shall comply with the
56 notification provisions of paragraph (2) (c) by entering the
57 substitution in the institution's written medical record system
58 or electronic medical record system.

576-04910-13

2013732c2

59 (4) The board shall maintain on its public website a
60 current list of biological products that the United States Food
61 and Drug Administration has determined are biosimilar and
62 interchangeable as provided in paragraph (2)(a).

63 Section 3. This act shall take effect July 1, 2013.